Lineage Cell Therapeutics (LCTX) Accumulated Expenses (2011 - 2026)

Lineage Cell Therapeutics has reported Accumulated Expenses for 16 years, with the latest figure at $1.2 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses fell 40.7% year-over-year to $1.2 million; the trailing twelve-month figure through Mar 2026 stood at $1.2 million (down 40.7% YoY), and the FY2025 full-year result was $1.1 million, down 8.44% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $1.2 million, up from $1.1 million in the prior quarter.
• The five-year high for Accumulated Expenses was $21.0 million in Q1 2022, with the low at $349000.0 in Q3 2023.
• Historically, Accumulated Expenses has averaged $2.8 million across 5 years, with a median of $1.9 million in 2022.
• Annual changes were most pronounced in 2022 — Accumulated Expenses soared 1585.39% — and 2023, when it slumped 98.08%.
• Lineage Cell Therapeutics' Accumulated Expenses stood at $2.4 million in 2022, then surged by 31.11% to $3.1 million in 2023, then slumped by 61.67% to $1.2 million in 2024, then slipped by 8.44% to $1.1 million in 2025, then rose by 12.59% to $1.2 million in 2026.
• The last three Accumulated Expenses figures came in at $1.2 million (Q1 2026), $1.1 million (Q4 2025), and $2.5 million (Q3 2025), per Business Quant data.